Business Wire

The Merck Healthcare Business Standardizes on Veeva CRM Globally to Improve Commercial Execution Across Channels

Del

Veeva Systems (NYSE:VEEV) today announced that the Healthcare business of Merck has selected Veeva CRM to improve operating efficiency and commercial effectiveness in Europe, Middle East, and Africa (EMEA). Building on the multi-year partnership with Veeva and following its success throughout North America, Latin America, and Asia Pacific, the business is now standardizing on multichannel Veeva CRM globally.

In addition to core Veeva CRM, the Healthcare business of Merck is expanding use of Veeva CLM, Veeva CRM Approved Email, and Veeva CRM MyInsights across the world. These solutions will enable the business to deliver a seamless customer experience across all channels, including face-to-face, email, and web.

“Understanding our customers and delivering them the right information at the right time through the right channel is key to our commercial strategy,” said Chetak Buaria, global head of commercial excellence of the Healthcare business at Merck. “We are unifying on a single global CRM solution to deliver on this vision with Veeva as our trusted global partner.”

“Veeva is committed to helping life sciences companies drive effective engagement with healthcare professionals,” said Paul Shawah, senior vice president of Veeva Commercial Cloud. “We are proud to team with the Healthcare business of Merck on their important mission to bring innovative medicines to market.”

Additional Information
For more on Veeva Vault CRM Suite, visit: veeva.com/eu/CRM-suite
Connect with Veeva on LinkedIn: linkedin.com/company/veeva-systems
Follow @veeva_eu on Twitter: twitter.com/veeva_eu
Like Veeva on Facebook: facebook.com/veevasystems

About Veeva Systems

Veeva Systems Inc. is the leader in cloud-based software for the global life sciences industry. Committed to innovation, product excellence, and customer success, Veeva serves more than 700 customers, ranging from the world's largest pharmaceutical companies to emerging biotechs. Veeva is headquartered in the San Francisco Bay Area, with offices throughout North America, Europe, Asia, and Latin America. For more information, visit veeva.com/eu.

About Merck

Merck, a leading science and technology company, operates across healthcare, life science and performance materials. Around 52,000 employees work to make a positive difference to millions of people’s lives every day by creating more joyful and sustainable ways to live. From advancing gene editing technologies and discovering unique ways to treat the most challenging diseases to enabling the intelligence of devices – the company is everywhere. In 2018, Merck generated sales of € 14.8 billion in 66 countries.

Scientific exploration and responsible entrepreneurship have been key to Merck’s technological and scientific advances. This is how Merck has thrived since its founding in 1668. The founding family remains the majority owner of the publicly listed company. Merck holds the global rights to the Merck name and brand. The only exceptions are the United States and Canada, where the business sectors of Merck operate as EMD Serono in healthcare, MilliporeSigma in life science, and EMD Performance Materials.

Forward-looking Statements

This release contains forward-looking statements, including the market demand for and acceptance of Veeva’s products and services, the results from use of Veeva’s products and services, and general business conditions, particularly in the life sciences industry. Any forward-looking statements contained in this press release are based upon Veeva’s historical performance and its current plans, estimates, and expectations, and are not a representation that such plans, estimates, or expectations will be achieved. These forward-looking statements represent Veeva’s expectations as of the date of this press announcement. Subsequent events may cause these expectations to change, and Veeva disclaims any obligation to update the forward-looking statements in the future. These forward-looking statements are subject to known and unknown risks and uncertainties that may cause actual results to differ materially. Additional risks and uncertainties that could affect Veeva’s financial results are included under the captions, “Risk Factors” and “Management’s Discussion and Analysis of Financial Condition and Results of Operations,” in the company’s filing on Form 10-K for the period ended January 31, 2019. This is available on the company’s website at veeva.com under the Investors section and on the SEC’s website at sec.gov. Further information on potential risks that could affect actual results will be included in other filings Veeva makes with the SEC from time to time.

Contact information

Roger Villareal
Veeva Systems
925-264-8885
roger.villareal@veeva.com

Kiran May
Veeva Systems
+44-796-643-2912
kiran.may@veeva.com

Om Business Wire

Business Wire
Business Wire
24 Martin Lane
EC4R 0DR London

+44 20 7626 1982http://www.businesswire.co.uk

(c) 2018 Business Wire, Inc., All rights reserved.

Business Wire, a Berkshire Hathaway company, is the global leader in multiplatform press release distribution.

Følg saker fra Business Wire

Registrer deg med din epostadresse under for å få de nyeste sakene fra Business Wire på epost fortløpende. Du kan melde deg av når som helst.

Siste saker fra Business Wire

Nordson EFD Introduces the Contact versus Jet Dispensing White Paper25.4.2019 12:16:00 CESTPressemelding

Nordson EFD , a Nordson company (NASDAQ: NDSN), the world’s leading precision fluid dispensing systems manufacturer, is pleased to introduce its Contact vs. Jet Dispensing white paper. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20190425005027/en/ As products continue to get smaller and smaller, Nordson EFD has developed new solutions to address this growing need to apply precise, repeatable micro-deposits of assembly fluids in production processes worldwide. “We understand the challenges manufacturers face when their process requires bonding tiny substrates and components together,” said Peter Langer, Business Unit Director of Valves at Nordson EFD. “The deposit tolerance requirements are considerable. And there are a number of variables to consider in order to choose the right dispensing method.” This white paper helps manufacturers understand the difference between two of the most common dispensing methods. Contact dispe

Hologic Launches Trident® HD Specimen Radiography System in United States, Canada and Europe25.4.2019 12:15:00 CESTPressemelding

Hologic, Inc. (Nasdaq: HOLX) today announced global commercial availability of the Trident® HD specimen radiography system, a next-generation solution that delivers enhanced image quality, improved workflow and instant sample verification during breast-conserving surgeries and stereotactic breast biopsies.1 This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20190425005180/en/ Trident® HD Specimen Radiography System (Photo: Business Wire) The Trident products are the only specimen radiographs on the market to use amorphous selenium direct capture imaging – the same detector technology used in Hologic’s 3Dimensions™ mammography system – to generate crisp, clear, high-resolution images. The new Trident HD system, which recently received FDA clearance in the US and a CE Mark in Europe, also features a bigger detector that allows for complete imaging of larger breast surgical specimens, along with a wide range of surgical and biopsy sa

Velodyne Lidar, Nikon Announce Manufacturing Agreement for Mass Production of Velodyne Lidar Sensors25.4.2019 12:00:00 CESTPressemelding

Velodyne Lidar, Inc. today announced an agreement with Nikon Corporation, under which Sendai Nikon Corporation, a Nikon subsidiary, will manufacture lidar sensors for Velodyne with plans to start mass production in the second half of 2019. The partnership cements Velodyne’s manufacturing plan and expands its lead in the global lidar sensor market. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20190425005236/en/ Velodyne provides the smartest, most powerful lidar solutions for vehicle autonomy and driver assistance. (Photo: Business Wire) “Mass production of our high-performance lidar sensors is key to advancing Velodyne’s immediate plans to expand sales in North America, Europe, and Asia,” said Marta Hall, President and CBDO, Velodyne Lidar. “With this partnership, Velodyne affirms its leadership role in designing, producing, and selling lidar for worldwide implementation. For years, Velodyne has been perfecting lidar technol

Gilead Announces Topline Data From Phase 3 STELLAR-3 Study of Selonsertib in Bridging Fibrosis (F3) Due to Nonalcoholic Steatohepatitis (NASH)25.4.2019 12:00:00 CESTPressemelding

Gilead Sciences, Inc. (Nasdaq: GILD) today announced that STELLAR-3, a Phase 3, randomized, double-blind, placebo-controlled study evaluating the safety and efficacy of selonsertib, an investigational, once daily, oral inhibitor of apoptosis signal-regulating kinase 1 (ASK1), for patients with bridging fibrosis (F3) due to nonalcoholic steatohepatitis (NASH), did not meet the pre-specified week 48 primary endpoint of a ≥ 1-stage histologic improvement in fibrosis without worsening of NASH. In the study of 802 enrolled and dosed patients, 9.3 percent of patients treated with selonsertib 18 mg (p=0.42 versus placebo) and 12.1 percent of patients treated with selonsertib 6 mg (p=0.93) achieved a ≥ 1-stage improvement in fibrosis according to the NASH Clinical Research Network (CRN) classification without worsening of NASH after 48 weeks of treatment, versus 13.2 percent with placebo. Selonsertib was generally well tolerated and safety results were consistent with prior studies. “While we

Forter Readies Merchants with Launch of PSD2-Compliant Solution25.4.2019 11:25:00 CESTPressemelding

Forter, the leading e-commerce fraud prevention company, today launches its PSD2-compliant merchant offering, Forter PSD2 Solution for Merchants . The comprehensive, payment processor-agnostic solution enables merchants to dynamically route customers to the path of least friction required, prevent all types of fraud and violations of business policies, and optimise the customer’s payment experience – all while meeting full PSD2 compliance. As of 14 September 2019, the revised Payment Services Directive (PSD2) introduces the requirement for merchants to authenticate online transactions within the European Economic Area using Strong Customer Authentication (SCA). Under SCA, merchants have to introduce additional friction into the purchasing process for customers, which will lead to increased drop-off rates, reduce overall conversion rates, and provide a poor customer experience. These changes could ultimately hurt revenue, so merchants must mitigate these challenges and minimise the impa

The Smarter E Europe – Explore Sector Coupling for Yourself at Europe’s Largest Platform for the Energy Industry25.4.2019 09:53:00 CESTPressemelding

The innovation hub The smarter E Europe, encompassing the exhibitions Intersolar Europe, ees Europe, Power2Drive Europe and EM-Power, was launched in 2018 and has seen impressive growth ever since. It will be held for the second time from May 15–17, 2019 at Messe München and will now cover 10 exhibition halls, making it Europe’s largest energy industry event. This growth is due in large part to the upward trend in renewable energies. Since 2010, the proportion of energy generated worldwide from renewable sources has risen from 20 to 25 percent. By 2030, we’re looking at a jump to around 60 percent. In Germany, an average of 45 percent of all electricity generated already came from renewables in the first quarter of 2019. This dynamism is stimulating innovation and shaping the modern energy industry. The buzzword of the hour is sector coupling – a unification of the previously independent electricity, heating and transportation sectors. For instance, a photovoltaic (PV) installation in